Destiny Pharma (DEST)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 37.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 74.00
  • 52 Week Low: 31.50
  • Currency: UK Pounds
  • Shares Issued: 43.87m
  • Volume: 3,408
  • Market Cap: £16.45m
  • RiskGrade: 240

Destiny Pharma pleased with latest XF-73 results at it proceeds with next phase

By Josh White

Date: Wednesday 16 Oct 2019

LONDON (ShareCast) - (Sharecast News) - Clinical stage biotechnology company Destiny Pharma reported on the publication of results from a positive phase 1 clinical study in 60 healthy United States volunteers using a nasal gel formulation of its lead drug, XF-73 (exeporfinium chloride), on Wednesday.
The AIM-traded firm said the headline results from the study were previously announced on 5 September.

It said the reported US study was independently conducted and sponsored by the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health.

In addition to the study reporting a favourable safety and local tolerability profile of the nasal gel formulation, the primary objective, the study also noted - as expected - that exposure to XF-73 produced a rapid reduction in levels of nasal S. aureus in all subjects.

Destiny Pharma said it was initially developing a nasal gel formulation of XF-73 as a novel therapy to prevent post-surgical infection, including those from methicillin resistant S. aureus (MRSA), as nasal carriage was the source of at least 80% of S.aureus or MRSA post-surgical bacterial infections.

The company said it was currently conducting a 200 patient multi-centre, randomised, blinded, placebo-controlled phase 2b study of a single concentration of XF-73 nasal gel.

That was to assess the anti-staphylococcal effect of XF-73 on S. aureus nasal carriage in US and European patients scheduled for cardiac surgical procedures deemed to be at high risk of postoperative S. aureus infection.

Headline results from that trial were anticipated in mid-2020.

"The full results from this positive phase 1 clinical study, independently conducted and sponsored by the NIH, underscores our confidence in the potential of XF-73 as a novel treatment to prevent the occurrence of post-surgical S. aureus bacterial infections which is a significant commercial opportunity," said chief executive officer Neil Clark.

"Importantly, there is no evidence to date suggesting that XF-73 causes bacterial resistance which is in contrast to current preventative treatments such as the application of the antibiotic mupirocin, which the use of is increasingly blunted by the rising incidence of resistant strains of S. aureus.

"We look forward to reporting headline data in mid-2020 from our ongoing 200 patient phase 2b trial that is assessing the ability of XF-73 to reduce nasal levels of S. aureus in patients at high risk of infection that are undergoing surgery."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Destiny Pharma Market Data

Currency UK Pounds
Share Price 37.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 74.00
52 Week Low 31.50
Volume 3,408
Shares Issued 43.87m
Market Cap £16.45m
RiskGrade 240

Destiny Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
20.26% below the market average20.26% below the market average20.26% below the market average20.26% below the market average20.26% below the market average
7.14% above the sector average7.14% above the sector average7.14% above the sector average7.14% above the sector average7.14% above the sector average
Price Trend
53.24% below the market average53.24% below the market average53.24% below the market average53.24% below the market average53.24% below the market average
78.95% below the sector average78.95% below the sector average78.95% below the sector average78.95% below the sector average78.95% below the sector average
Income Not Available
Growth Not Available

Destiny Pharma Dividends

No dividends found

Trades for 01-Jul-2020

Time Volume / Share Price
10:10 200 @ 37.95p
08:02 3,208 @ 38.00p

Destiny Pharma Key Personnel

CEO Neil Clark
Chair Nick Rodgers

Top of Page